eToro
By eToro
15753 views

5 companies developing a coronavirus vaccine: which one will be the first to market?

As the Covid-19 pandemic makes its way around the globe and countries desperately try to contain the virus, the need for a vaccine is abundantly clear. And time is of the essence.

The following companies are currently in a race to develop a coronavirus vaccine that can be brought to market as soon as possible.

Sanofi
The French drugmaker has a team of scientists in the US, working in collaboration with the Biomedical Advanced Research and Development Authority (BARDA) on a vaccine which leverages progress that the company previously made on a vaccine for SARS. SARS is also part of the coronavirus family, which may give Sanofi an edge in the development of a Covid-19 vaccine.


Your capital is at risk. This is not investment advice. 

Gilead Sciences
Gilead is at work on a treatment for patients infected with Covid-19, which has already helped one patient in the US and will soon be sent to Asia for more comprehensive late-stage clinical testing. There, studies will determine whether the treatment can reverse infection, help patients recover more quickly and be released from the hospital faster.


Your capital is at risk. This is not investment advice. 

GlaxoSmithKline
British pharmaceutical giant GSK is one of the world’s leading vaccine makers, well known for having brought the human papillomavirus (HPV) and seasonal flu vaccines to market. GSK is now providing the necessary technology to a Chinese biotech firm to develop a vaccine for Covid-19.


Your capital is at risk. This is not investment advice. 

Regeneron Pharmaceuticals
The New York biotech company, Regeneron is developing a treatment that could protect people from contracting the coronavirus. The treatment uses antibodies from mice that have been genetically modified with immune systems to mimic those of humans. The company claims that it could be ready for human testing as early as August.


Your capital is at risk. This is not investment advice. 

Johnson and Johnson
Johnson and Johnson has partnered with the Biomedical Advanced Research and Development Authority and BARDA to develop treatments for Covid-19. The American pharma giant is utilising its vaccine platform technology previously developed for an experimental Ebola vaccine.


Your capital is at risk. This is not investment advice. 

 

While experts say that we are at least a year away from a coronavirus vaccine that will be available to the public, in the meantime, stocks from these companies are sure to see movement as any of them gain ground in the vaccine’s development. Be sure to add them to your watchlist to stay informed.


Your capital is at risk. This is not investment advice. 

 

 

15753 views